Andocs Pharmacos India Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 6.00 M
as on 17-07-2024
- Company Age 4 Year, 13 Days
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Profit 6861.29%
(FY 2022)
- Ebitda 10101.29%
(FY 2022)
- Net Worth 4267.63%
(FY 2022)
- Total Assets 4381.05%
(FY 2022)
About Andocs Pharmacos India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 6.00 M, as per Ministry of Corporate Affairs (MCA) records.
Chandrakant and Ranjeet Sinha serve as directors at the Company.
- CIN/LLPIN
U24239UP2020PTC139034
- Company No.
139034
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Dec 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Noida, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Andocs Pharmacos India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandrakant  | Director | 09-Dec-2020 | Current |
| Ranjeet Sinha | Director | 09-Dec-2020 | Current |
Financial Performance of Andocs Pharmacos India.
Andocs Pharmacos India Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 6861.29% increase in profit. The company's net worth Soared by an impressive increase of 4267.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Andocs Pharmacos India?
In 2022, Andocs Pharmacos India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Suryaveda Cosmeceuticals Private LimitedActive 5 years 4 monthsChandrakant and Ranjeet Sinha are mutual person
Hanisan Healthcare Private LimitedActive 6 years 16 daysChandrakant and Ranjeet Sinha are mutual person
Prakritimagic Wellness Private LimitedActive 10 months 21 daysChandrakant and Ranjeet Sinha are mutual person
- Andosa Cosmetics India Private LimitedActive 6 years 4 months
Chandrakant and Ranjeet Sinha are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Andocs Pharmacos India?
Andocs Pharmacos India has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Andocs Pharmacos India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Andocs Pharmacos India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
